Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06501963 · ClinicalTrials.gov registry record · Phase 4
Revealing Protective Immunity to Influenza Using Systems Immunology
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT06501963 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 51 participants.
The verdict
NCT06501963, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
The goals of this study are to better understand the human immune response to influenza vaccines, specifically the live attenuated (weakened) influenza vaccine given as a nasal spray. Better understanding why this vaccine does not work as well in adults as it does in children may help design better influenza vaccines.
Interventions
- BIOLOGICAL Live Attenuated Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2024-10-14 |
| Est. Completion | 2025-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06501963
The ClinicalTrials.gov registry entry for NCT06501963 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Live Attenuated Influenza Vaccine is the first listed.
NCT06501963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06501963 about?
NCT06501963 is a clinical study titled "Revealing Protective Immunity to Influenza Using Systems Immunology". The goals of this study are to better understand the human immune response to influenza vaccines, specifically the live attenuated (weakened) influenza vaccine given as a nasal spray. Better understanding why this vaccine does not work as well in adults as it does in children may help design better ...
What is the current status of trial NCT06501963?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2024-10-14. Estimated completion is 2025-04-01.
What interventions are being tested in trial NCT06501963?
The interventions under investigation include: Live Attenuated Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06501963?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.